Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
JAGX 
Jaguar Animal Health Inc (JAGX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/05/2025: JAGX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $25.5
1 Year Target Price $25.5
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -88.61% | Avg. Invested days 17 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.03M USD | Price to earnings Ratio - | 1Y Target Price 25.5 |
Price to earnings Ratio - | 1Y Target Price 25.5 | ||
Volume (30-day avg) 2 | Beta -0.1 | 52 Weeks Range 1.00 - 33.25 | Updated Date 12/6/2025 |
52 Weeks Range 1.00 - 33.25 | Updated Date 12/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.58 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-14 | When - | Estimate -0.22 | Actual -6.28 |
Profitability
Profit Margin - | Operating Margin (TTM) -234.77% |
Management Effectiveness
Return on Assets (TTM) -38.01% | Return on Equity (TTM) -411.57% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 34668553 | Price to Sales(TTM) 0.34 |
Enterprise Value 34668553 | Price to Sales(TTM) 0.34 | ||
Enterprise Value to Revenue 2.94 | Enterprise Value to EBITDA -0.63 | Shares Outstanding 3735837 | Shares Floating 3061406 |
Shares Outstanding 3735837 | Shares Floating 3061406 | ||
Percent Insiders 24.37 | Percent Institutions 2.33 |
Upturn AI SWOT
Jaguar Animal Health Inc
Company Overview
History and Background
Jaguar Animal Health Inc. was a company focused on developing and commercializing veterinary pharmaceuticals. Founded in 2013, its primary focus was on novel anti-infective and anti-inflammatory products for companion animals and livestock. The company aimed to address unmet medical needs in veterinary medicine. However, the company faced significant financial and operational challenges, leading to its eventual delisting and likely cessation of operations in its original form.
Core Business Areas
- Veterinary Pharmaceuticals Development: Jaguar Animal Health Inc. was engaged in the research, development, and commercialization of prescription drugs for animals. This included a focus on therapeutics for various animal health conditions, particularly in areas like gastrointestinal health and infectious diseases.
Leadership and Structure
Information regarding Jaguar Animal Health Inc.'s specific leadership team and organizational structure prior to its operational decline is not readily available or publicly maintained in a current, active capacity. Given its status, the original leadership and structure are no longer pertinent to an ongoing business.
Top Products and Market Share
Key Offerings
- N-acetylcysteine (NAC) for Canine Parvovirus: Jaguar Animal Health Inc. pursued the development of its lead product candidate, crofelemer (Canine Atrial Fibrillation - CAF), a botanical drug derived from C. grandis. This was intended as a treatment for canine parvovirus. Competitors in veterinary critical care and infectious disease treatments include companies like Zoetis, Boehringer Ingelheim Animal Health, and Elanco Animal Health.
Market Dynamics
Industry Overview
The veterinary pharmaceutical market is a significant and growing sector driven by increasing pet ownership, demand for advanced animal healthcare, and the rise of companion animal humanization. The livestock sector also contributes, focusing on animal welfare and productivity. Key trends include the development of novel therapeutics, biologics, and diagnostics.
Positioning
Jaguar Animal Health Inc. aimed to position itself as an innovator in novel veterinary therapeutics, focusing on unmet medical needs. However, its limited product pipeline and financial struggles hindered its ability to establish a significant market share or competitive advantage.
Total Addressable Market (TAM)
The global animal health market is substantial and growing, estimated to be in the tens of billions of US dollars annually. Jaguar Animal Health Inc.'s position within this TAM was minimal due to its developmental stage and eventual operational issues. The company's ambition was to carve out a niche within specific therapeutic areas, but it did not achieve significant scale.
Upturn SWOT Analysis
Strengths
- Focus on novel botanical drug development for veterinary use.
- Potential to address unmet medical needs in animal health.
Weaknesses
- Limited product portfolio and revenue generation.
- History of financial instability and funding challenges.
- Significant reliance on a few key product candidates.
- Lack of established market presence and distribution network.
Opportunities
- Growing demand for advanced veterinary therapeutics.
- Increasing expenditure on pet healthcare.
- Potential for partnerships and collaborations in the animal health sector.
Threats
- Intense competition from established animal health companies.
- Regulatory hurdles and lengthy approval processes for new drugs.
- High cost of drug development and commercialization.
- Economic downturns impacting consumer spending on pet care.
Competitors and Market Share
Key Competitors
- Zoetis Inc. (ZTS)
- Elanco Animal Health Incorporated (ELAN)
- Boehringer Ingelheim Animal Health (Private Company, no US Stock Symbol)
- Merck Animal Health (part of Merck & Co., Inc. - MRK)
Competitive Landscape
Jaguar Animal Health Inc. faced a highly competitive landscape dominated by large, established players with extensive R&D capabilities, global distribution networks, and broad product portfolios. Its competitive disadvantages included limited financial resources, a narrow product focus, and a lack of commercialization experience.
Growth Trajectory and Initiatives
Historical Growth: Jaguar Animal Health Inc. did not achieve significant historical growth in terms of revenue or market presence. Its trajectory was characterized by attempts to advance product development through clinical trials and regulatory processes.
Future Projections: Future projections for Jaguar Animal Health Inc. are not applicable as the company is no longer an active, publicly traded entity with ongoing operations. Analyst estimates would have been contingent on successful product development and regulatory approval.
Recent Initiatives: In its operational history, recent initiatives would have focused on advancing its product pipeline, seeking regulatory approvals, and exploring strategic partnerships. However, these efforts did not result in sustained growth or viability.
Summary
Jaguar Animal Health Inc. was a development-stage company in the animal health sector that faced significant challenges and ultimately ceased operations in its original form. Its focus on novel botanical drugs showed promise, but financial instability and competitive pressures prevented commercial success. The company needs to learn from its operational and financial shortcomings if any future ventures are to be successful.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Publicly available financial news and company filings (historical).
- Industry reports on the animal health market.
Disclaimers:
The information provided is based on publicly available data and is for informational purposes only. Jaguar Animal Health Inc. is no longer an actively operating company. This analysis reflects its historical status and market context. No investment advice is implied.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Jaguar Animal Health Inc
Exchange NASDAQ | Headquaters San Francisco, CA, United States | ||
IPO Launch date 2015-05-13 | Founder, CEO, President & Director Ms. Lisa A. Conte | ||
Sector Healthcare | Industry Biotechnology | Full time employees 49 | Website https://jaguar.health |
Full time employees 49 | Website https://jaguar.health | ||
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. The company operates through two segments, Animal Health and Human Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company offers Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.